You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Ann Arbor, Michigan-based Celsee offers instruments and consumables for isolating, detecting, and analyzing single cells.
The plaintiffs allege that TAI's heart transplant rejection test MyTAIHeart infringes on their patent for the non-invasive diagnosis of graft rejection.
The kit is designed for the qualitative detection of nucleic acid from SARS-CoV-2 nasal, nasopharyngeal, and oropharyngeal swab samples.
The Lexington, Massachusetts-based company also terminated a purchase agreement and raised the amount in it may raise in a public offering of its common stock to $95.
The company said it has recently expanded its manufacturing capacity to 500,000 tests per week and is planning to increase it another fourfold.
The molecular laboratory-developed test was authorized for use only in the Stanford Health Care Clinical Virology Laboratory.
The company said that contact between its sales reps and clinicians began to decline in March due to the COVID-19 pandemic, affecting mainly SelectMDx volumes.
Clinical test volume at the company is expected to grow 7 percent year over year but decreased significantly at the end of March due to the COVID-19 pandemic.
Under the Public Readiness and Emergency Preparedness Act, pharmacists qualify as "covered persons" to administer SARS-CoV-2 tests.
The company said the COVID-19 pandemic and resulting stay-at-home orders have led to a slowdown in testing service volumes in recent weeks.
The protein-protein interactions tallied in the project are expected to inform future studies of biology and disease in various tissue and cell types.
Drawing from its massive consumer genetic dataset and longitudinal survey data, 23andMe is searching for genetic features that might influence the severity of SARS-CoV-2 infections.
Among other projects, PacBio is working with LabCorp to sequence a large number of SARS-CoV-2 genomes from de-identified positive samples.
The firm plans to submit an EUA application for its quantitative Sanger sequencing COVID-19 test, which could run on hundreds of available CE instruments.
The investment bank said the company's molecular diagnostics have the potential to replace microarrays for cytogenetics analysis.
The data identified common variants that alter gene expression constantly across development, or predominantly during the prenatal or postnatal stages.
The collaboration includes setting up a new testing laboratory that will investigate the use of alternative chemical reagents for test kits.
Starting late March and into its fiscal fourth quarter, social distancing guidelines began significantly impacting test volume trends, the company said.
The real-time PCR test provides results in about four hours and has been validated on Thermo Fisher Scientific and Bio-Rad instruments.
Approximately 80 percent of gross product placements in the quarter were associated with interest in COVID-19 testing, the firm said
Researchers re-analyzed throat swabs collected from patients in Wuhan with influenza-like-illness and found that some were positive for SARS-Cov-2.
The researchers applied their approach to study the heterogeneity of immune cells and adapted a visualization tool to analyze the data.
The company said that three of its clinical laboratories have passed a COVID-19 external quality assessment by China's National Center for Clinical Laboratories.
United said it will distribute the test to international governments and healthcare organizations.
The company said its product and services revenues were about $24.5 million for the quarter, 15 percent higher than the same period last year.
Researchers in India plan to sequence SARS-CoV-2 isolates from around the country, according to LiveMint.
Mauro Ferrari has resigned as president of the European Research Council over its response to the COVID-19 pandemic, the Financial Times reports.
Stat News reports some health tech startups are laying off or furloughing workers.
In Genome Research this week: indels affecting microsatellites in cancer, analytical approach to find key regulatory elements, and more.